It’s that time of year again: the dreaded cold and flu season is on the horizon. But lurking in the shadows is a more sinister threat: RSV.

Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.

It often mimics the common cold, but RSV can quickly turn into bronchiolitis and pneumonia. “The older you get, the milder ...

Scientists searching for the origins of COVID-19 zeroed in on a short list of animals that possibly helped spread it to ...

Most people notice this when air pressure changes rapidly, such as when a plane ascends or descends. This happens because the pressurization of the cabin isn't perfect, and the ear pressure is higher ...

The study also pointed out that galectins, located on the spike protein of the virus, are an excellent target for drugs because it doesn't change much, making it easier to stop the virus from ...

After incorporating COVID-19–specific elements into an established stewardship program, antibiotic use fell by 29% from the ...

GSK recorded positive topline data in a late stage trial of its respiratory syncytial virus vaccine combined with a shingles vaccine in treating adults 50 years and older.

British drugmaker GSK said on Wednesday its respiratory syncytial virus (RSV) vaccine, when given together with its shingles ...

Global Respiratory Syncytial Virus Therapeutics Market was valued at approximately USD 5.88 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 12.82% over the forecast ...